Wes Tillott

EQS-News: Tillotts Pharma and TVM Capital Life Science Announce Formation of Mage Biologics to Develop Innovative Oral Antibody Therapy for Ulcerative Colitis

Retrieved on: 
목요일, 7월 20, 2023
TVM, PFC, Bureau of Oceans and International Environmental and Scientific Affairs, Clinical trial, General partnership, Inflammation, Ulcerative colitis, Investment, Patient, LSI, Mab, CFO, Therapy, Pharmaceutical industry, Vaccine, Wes Tillott

Mage Bio is the 10th early-stage or project-focused company (PFC) investment for TVM LSI II.

Key Points: 
  • Mage Bio is the 10th early-stage or project-focused company (PFC) investment for TVM LSI II.
  • Mage Biologics plans to advance to clinical proof of concept a novel, orally administered, humanized monoclonal antibody (mAb) bioengineered for optimal potency and tissue penetration.
  • Thomas A. Tóth von Kiskér, CEO and Board Director of Tillotts, commented: "We are excited to team up with TVM Capital Life Science to advance this oral antibody in ulcerative colitis, a lifelong disease profoundly impacting the patients’ quality of life.
  • The collaboration with TVM underpins Tillotts’ leading role in developing and commercializing innovative products in the gastrointestinal field.”
    "TVM Capital Life Science is proud to have enabled the creation of Mage Biologics.

Tillotts Pharma and TVM Capital Life Science Announce Formation of Mage Biologics to Develop Innovative Oral Antibody Therapy for Ulcerative Colitis

Retrieved on: 
목요일, 7월 20, 2023
TVM, PFC, Bureau of Oceans and International Environmental and Scientific Affairs, Clinical trial, General partnership, Inflammation, Ulcerative colitis, Investment, Patient, LSI, Mab, CFO, Therapy, Pharmaceutical industry, Vaccine, Wes Tillott

MONTREAL and MUNICH, Germany and RHEINFELDEN, Switzerland, July 20, 2023 (GLOBE NEWSWIRE) -- TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, together with specialty pharma company, Tillotts Pharma (“Tillotts”), today announced that the companies will jointly invest up to USD 28 million in the newly formed U.S.-based biotechnology company, Mage Biologics Inc. (“Mage Bio”). TVM will invest with its fund TVM Life Science Innovation II SCSp (“TVM LSI II”) and will provide strategic advice to Mage Bio, with Dr. Sascha Berger, General Partner, joining the Board of Directors and Dr. Ivan Shaw, Principal, serving as a Board Observer. Mage Bio is the 10th early-stage or project-focused company (PFC) investment for TVM LSI II.

Key Points: 
  • Mage Bio is the 10th early-stage or project-focused company (PFC) investment for TVM LSI II.
  • Mage Biologics plans to advance to clinical proof of concept a novel, orally administered, humanized monoclonal antibody (mAb) bioengineered for optimal potency and tissue penetration.
  • Thomas A. Tóth von Kiskér, CEO and Board Director of Tillotts, commented: "We are excited to team up with TVM Capital Life Science to advance this oral antibody in ulcerative colitis, a lifelong disease profoundly impacting the patients’ quality of life.
  • The collaboration with TVM underpins Tillotts’ leading role in developing and commercializing innovative products in the gastrointestinal field.”
    "TVM Capital Life Science is proud to have enabled the creation of Mage Biologics.

Tillotts Standardizes on Veeva Commercial Cloud Applications to Power Digital Engagement in Europe

Retrieved on: 
수요일, 9월 28, 2022
Cloud, Veeva Systems, NYSE, Clostridioides, Clostridioides difficile infection, Acquisition, Compliance, Industry, Hand, Human, United Kingdom, HCPS, IBD, Marketing, SEC, CDI, Professional corporation, Pharmaceutical industry, Cryptocurrency, Wes Tillott

BARCELONA, Spain, Sept. 28, 2022 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Tillotts Pharma AG is using Veeva CRM and Veeva Vault PromoMats to advance digital engagement in France, Germany, Italy, Spain, and the United Kingdom. With these connected Veeva Commercial Cloud applications, the company can better coordinate relevant interactions with healthcare professionals (HCPs), delivering tailored and compliant multi-channel content.

Key Points: 
  • With these connected Veeva Commercial Cloud applications, the company can better coordinate relevant interactions with healthcare professionals (HCPs), delivering tailored and compliant multi-channel content.
  • "With Veeva CRM and Veeva Vault PromoMats we gain a complete view of customers and content to enable relevant engagement across Europe," said Adrian Hill, global head of commercial operations at Tillotts.
  • As part of its digital engagement strategy, Tillotts is also using Veeva OpenData , embedding healthcare ecosystem reference data in Veeva CRM for real-time insights.
  • "Tillotts is leading the way toward commercial excellence, creating seamless collaboration between sales, medical, and marketing to better serve its customers," said Philipp Luik, vice president of commercial strategy at Veeva Europe.

Tillotts Pharma AG announces that DIFICLIRTM (fidaxomicin) is recommended for the treatment of Clostridioides difficile infection (CDI) by ESCMID

Retrieved on: 
수요일, 12월 8, 2021
Health, Infectious Diseases, Clinical Trials, Research, Pharmaceutical, Science, Medical microbiology, Disease, CDI, European Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of America, News, Risk factor, ESCMID, Recurrence, Goldenberg, Dis, Clostridioides difficile infection, Microbiota, Infection, PMID, Acquisition, Plasma protein binding, Clostridioides, Meta-analysis, ECDC, IDSA, Patient, IBD, Consultant, Mortality, OTC, Human, Tesco international operations, Clostridium difficile, Systematic review, Vancomycin, European Centre for Disease Prevention and Control, Lancet, University, Tablet, Guideline, Society, Wes Tillott, Fidaxomicin, CDAD, Health care, MD, Adult, RNA, Clinical trial, Trial of the century, Vaccine, Pharmaceutical industry, DIFICLIRTM, Tillotts, Zeria, DIFICLIRTM, TILLOTTS, ZERIA

Despite the endemic nature of C. difficile in many healthcare settings, sustained clinical cure and prevention of recurrence are achievable treatment goals for CDI.

Key Points: 
  • Despite the endemic nature of C. difficile in many healthcare settings, sustained clinical cure and prevention of recurrence are achievable treatment goals for CDI.
  • European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults.
  • Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial.
  • Tillotts Pharma AG, part of the Japanese Zeria Group, is a fast-growing specialty pharma company with over 300 employees in Switzerland and abroad.